Molecular targets for selective killing of TRAIL-resistant leukemic cells

Bibliography

• Di Pietro R, Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 2004;201:331-40
   PubMed Web of Science ®Google Scholar
• Corallini F, Celeghini C, Rimondi E, TRAIL down-regulates the release of osteoprotegerin (OPG) by primary stromal cells. J Cell Physiol 2010: published online 6 December 2010, doi: 10.1002/jcp.22564
   Google Scholar
• Zauli G, Corallini F, Bossi F, Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007;110:536-43
   PubMed Web of Science ®Google Scholar
• Zauli G, Melloni E, Capitani S, Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 2009;66:841-5
   PubMed Web of Science ®Google Scholar
• Secchiero P, Zauli G. TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Op Hematol 2008;15:42-8
   PubMed Web of Science ®Google Scholar
• Manzo F, Nebbioso A, Miceli M, TNF-related apoptosis-inducing ligand: signalling of a ‘smart’ molecule. Int J Biochem Cell Biol 2009;41:460-6
   PubMed Web of Science ®Google Scholar
• Whiteside TL. The role of death receptor ligands in shaping tumor microenvironment. Immunol Invest 2007;36:25-46
   PubMed Web of Science ®Google Scholar
• Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 2010;14:1091-108
   PubMed Web of Science ®Google Scholar
• Inukai T, Zhang X, Goto M, Resistance of infant leukemia with MLL rearrangement to tumor necrosis factor-related apoptosis-inducing ligand: a possible mechanism for poor sensitivity to antitumor immunity. Leukemia 2006;20:2119-29
   PubMed Web of Science ®Google Scholar
• Mullican SE, Shuo Zhang S, Konopleva M, Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med 2007;13:730-5
   PubMed Web of Science ®Google Scholar
• Suh WS, Kim YS, Schimmer AD, Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL. Leukemia 2003;17:2122-9
   PubMed Web of Science ®Google Scholar
• Riccioni R, Senese M, Diverio D, M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis. Br J Haematol 2007;139:194-205
   PubMed Web of Science ®Google Scholar
• van Blitterswijk WJ, Verheij M. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr Pharm Des 2008;14:2061-74
   PubMed Web of Science ®Google Scholar
• Tazzari PL, Tabellini G, Ricci F, Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myelogenous leukemia cells. Cancer Res 2008;68:9394-403
   PubMed Web of Science ®Google Scholar
• David E, Sinha R, Chen J, Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors. Clin Cancer Res 2008;14:5090-8
   PubMed Web of Science ®Google Scholar
• Fu L, Li YD, Elrod HA, C-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL. Mol Cancer 2010;9:215
   PubMedGoogle Scholar
• Gajate C, Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007;109:711-19
   PubMed Web of Science ®Google Scholar
• Secchiero P, di Iasio MG, Gonelli A, Zauli G. The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr Pharm Des 2008;14:2100-10
   PubMed Web of Science ®Google Scholar
• Secchiero P, Zerbinati C, di Iasio MG, Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway Nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 2007;8:395-403
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zuber J, Diaz-Flores E, p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev 2010;24:1389-402
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Yamada Y, Iha H, Activation of p53 by Nutlin-3, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells. Leukemia 2009;23:2090-101
   PubMed Web of Science ®Google Scholar
• Shih TT, Hou HA, Liu CY, Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. Blood 2009;113:3161-7
   PubMed Web of Science ®Google Scholar
• Madlambayan GJ, Meacham AM, Hosaka K, Leukemia regression by vascular disruption and antiangiogenic therapy. Blood 2010;116:1539-47
   PubMed Web of Science ®Google Scholar
• Secchiero P, Corallini F, Gonelli A, Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res 2007;100:61-9
   PubMed Web of Science ®Google Scholar
• Szegezdi E, Reis CR, Van Der Sloot A, Targeting AML through DR4 with a novel variant of rhTRAIL. J Cell Mol Med 2010: published online 10 November 2010, doi: 10.1111/j.1582-4934.2010.01211.x
   Google Scholar
• Sakoe Y, Sakoe K, Kirito K, FOXO3A as a key molecule for all-trans retinoic acid-induced granulocytic differentiation and apoptosis in acute promyelocytic leukemia. Blood 2010;115:3787-95
   PubMed Web of Science ®Google Scholar
• Nebbioso A, Clarke N, Voltz E, Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005;11:77-84
   PubMed Web of Science ®Google Scholar
• Secchiero P, Gonelli A, Mirandola P, Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood 2002;100:2421-9
   PubMed Web of Science ®Google Scholar
• Simons MP, Leidal KG, Nauseef WM, Griffith TS. TNF-related apoptosis-inducing ligand (TRAIL) is expressed throughout myeloid development, resulting in a broad distribution among neutrophil granules. J Leukoc Biol 2008;83:621-9
   Google Scholar
• Tecchio C, Huber V, Scapini P, IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 2004;103:3837-44
   PubMed Web of Science ®Google Scholar
• Mirandola P, Ponti C, Gobbi G, Activated human NK and CD8+ T cells express both TNF-related apoptosis inducing ligand (TRAIL) and TRAIL receptors, but are resistant to TRAIL-mediated cytotoxicity. Blood 2004;104:2418-24
   PubMed Web of Science ®Google Scholar
• Cho YS, Challa S, Clancy L, Chan FK. Lipopolysaccharide-induced expression of TRAIL promotes dendritic cell differentiation. Immunology 2010;130:504-15
   PubMedGoogle Scholar
• D'Asaro M, La Mendola C, Di Liberto D, Vgamma9Vdelta2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol 2010;184:3260-8
   PubMedGoogle Scholar
• Tanaka H, Ito T, Kyo T, Kimura A. Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients. Eur J Haematol 2007;78:389-98
   PubMed Web of Science ®Google Scholar
• De Carvalho DD, Binato R, Pereira WO, BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. Oncogene 2010;30:223-33
   PubMed Web of Science ®Google Scholar
• Park SJ, Kim MJ, Kim HB, Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP. Biochem J 2009;420:73-81
   PubMedGoogle Scholar
• Kikuchi S, Nagai T, Kunitama M, Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Sci 2007;98:1949-58
   PubMed Web of Science ®Google Scholar
• Yong AS, Keyvanfar K, Hensel N, Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 2009;113:875-82
   PubMed Web of Science ®Google Scholar
• Melloni E, Secchiero P, Celeghini C, Functional expression of TRAIL and TRAIL-R2 during human megakaryocytic development. J Cell Physiol 2005;204:975-82
   PubMed Web of Science ®Google Scholar
• Yang L, Wang L, Zhao CH, Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. Blood 2010;116:4307-16
   PubMedGoogle Scholar
• Tognon R, Gasparotto EP, Leroy JM, Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases. J Clin Pathol 2011;64:75-82
   PubMed Web of Science ®Google Scholar
• Gugliotta L, Bagnara GP, Catani L, In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia. Br J Haematol 1989;71:177-81
   PubMed Web of Science ®Google Scholar
• Zerafa N, Westwood JA, Cretney E, TRAIL deficiency accelerates hematological malignancies. J Immunol 2005;175:5586-90
   PubMed Web of Science ®Google Scholar
• Secchiero P, di Iasio MG, Gonelli A, Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70. J Cell Physiol 2007;213:229-36
   PubMedGoogle Scholar
• Rossi FM, Del Principe MI, Rossi D, Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. J Transl Med 2010;8:23
   PubMed Web of Science ®Google Scholar
• Secchiero P, Corallini F, di Iasio MG, TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 2005;105:3413-19
   PubMed Web of Science ®Google Scholar
• Kabore AF, Sun J, Hu X, The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis 2006;11:1175-93
   PubMed Web of Science ®Google Scholar
• Lagneaux L, Gillet N, Stamatopoulos B, Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response. Exp Hematol 2007;35:1527-37
   PubMed Web of Science ®Google Scholar
• Inoue S, Mai A, Dyer MJ, Cohen GM. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor related apoptosis- inducing ligand-induced apoptosis. Cancer Res 2006;66:6785-92
   PubMed Web of Science ®Google Scholar
• Natoni A, MacFarlane M, Inoue S, TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br J Haematol 2007;139:568-77
   PubMedGoogle Scholar
• Inoue S, Harper N, Walewska R, Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis. Mol Cancer Ther 2009;8:3088-97
   PubMed Web of Science ®Google Scholar
• Norian LA, Kucaba TA, Earel JK, Synergistic induction of apoptosis in primary B-CLL cells after treatment with recombinant TRAIL and histone deacetylase inhibitors. J Oncol 2009: published online 14 June 2009, doi:10.1155/2009/408038
   Google Scholar
• Lucas DM, Alinari L, West DA, The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One 2010;5:e10941
   PubMed Web of Science ®Google Scholar
• Loeder S, Zenz T, Schnaiter A, A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res 2009;69:8977-86
   PubMed Web of Science ®Google Scholar
• Frenzel LP, Patz M, Pallasch CP, Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis. Br J Haematol 2011;152:191-200
   PubMedGoogle Scholar
• Fakler M, Loeder S, Vogler M, Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009;113:1710-22
   PubMed Web of Science ®Google Scholar
• Lopez-Guerra M, Roue G, Perez-Galan P, p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541. Clin Cancer Res 2009;15:2767-76
   PubMed Web of Science ®Google Scholar
• Ishdorj G, Johnston JB, Gibson SB. Inhibition of constitutive activation of STAT3 by curcurbitacin-I (JSI-124) sensitized human B-leukemia cells to apoptosis. Mol Cancer Ther 2010;9:3302-14
   Google Scholar
• Lapalombella R, Andritsos L, Liu Q, Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 2010;115:2619-29
   PubMed Web of Science ®Google Scholar
• Szliszka E, Krol W. The role of dietary polyphenols in tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis for cancer chemoprevention. Eur J Cancer Prev 2011;20:63-9
   PubMed Web of Science ®Google Scholar
• Carter BZ, Mak DH, Schober WD, Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 2008;111:3742-50
   PubMed Web of Science ®Google Scholar
• Fas SC, Baumann S, Zhu JY, Wogonin sensitizes resistant malignant cells to TNFalpha- and TRAIL-induced apoptosis. Blood 2006;108:3700-6
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Yamada Y, Komiyama K, Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells. Blood 2006;107:679-88
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Yamada Y, Komiyama K, A novel natural compound, a Cycloanthranilylproline-derivative (Fuligocandin B), sensitizes leukemia cells to TRAIL-induced apoptosis through 15d-PGJ2 production. Blood 2007;110:1664-74
   PubMedGoogle Scholar
• Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nature Rev Cancer 2007;7:357-69
   PubMed Web of Science ®Google Scholar
• Russo M, Spagnuolo C, Volpe S, Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients. Br J Cancer 2010;103:642-8
   PubMed Web of Science ®Google Scholar
• Kim SH, Ricci MS, El-Deiry WS. Mcl-1: a gateway to TRAIL sensitization. Cancer Res 2008;68:2062-4
   PubMed Web of Science ®Google Scholar
• Rosato RR, Almenara JA, Coe S, Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 2007;67:9490-500
   PubMed Web of Science ®Google Scholar
• Meng XW, Lee SH, Dai H, Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem 2007;282:29831-46
   PubMed Web of Science ®Google Scholar
• Metzelder S, Wang Y, Wollmer E, Compassionate use of sorafenib in FLT3-ITD positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009;113:6567-71
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Gale RE, Frew ME, The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752-9
   PubMed Web of Science ®Google Scholar
• Ricci MS, Kim SH, Ogi K, Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007;12:66-80
   PubMed Web of Science ®Google Scholar
• Son JK, Varadarajan S, Bratton SB. TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1. Cell Death Differ 2010;17:1288-301
   PubMed Web of Science ®Google Scholar
• Conticello C, Adamo L, Vicari L, Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia. Acta Haematol 2008;120:19-30
   PubMed Web of Science ®Google Scholar
• Finlay D, Richardson RD, Landberg LK, Novel HTS strategy identifies TRAIL-sensitizing compounds acting specifically through the caspase-8 apoptotic axis. PLoS One 2010;5:e13375
   PubMedGoogle Scholar
• Petrak J, Toman O, Simonova T, Identification of molecular targets for selective elimination of TRAIL-resistant leukemia cells. From spots to in vitro assays using TOP15 charts. Proteomics 2009;9:5006-15
   PubMedGoogle Scholar
• Zamai L, Secchiero P, Pierpaoli S, TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 2000;95:3716-24
   PubMed Web of Science ®Google Scholar
• Campioni D, Secchiero P, Corallini F, The expression and release of TRAIL are increased in the bone marrow of patients affected by myelodysplastic syndromes (MDS): correlation with the degree of anemia and with the angiogenetic potential. Am J Pathol 2005;166:557-63
   PubMed Web of Science ®Google Scholar
• Carlo-Stella C, Lavazza C, Locatelli A, Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res 2007;13:2313-17
   PubMed Web of Science ®Google Scholar
• Lavazza C, Carlo-Stella C, Giacomini A, Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature. Blood 2010;115:2231-40
   PubMed Web of Science ®Google Scholar
• Secchiero P, Melloni E, Corallini F, Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells 2008;26:2955-63
   PubMed Web of Science ®Google Scholar
• Szegezdi E, O'Reilly A, Davy Y, Stem cells are resistant to TRAIL receptor-mediated apoptosis. J Cell Mol Med 2009;13:4409-14
   PubMedGoogle Scholar
• Grisendi G, Bussolari R, Cafarelli L, Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res 2010;70:3718-29
   PubMed Web of Science ®Google Scholar
• Loebinger MR, Sage EK, Davies D, Janes SM. TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population. Br J Cancer 2010;103:1692-7
   PubMedGoogle Scholar
• Mueller LP, Luetzkendorf J, Widder M, TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo. Cancer Gene Ther 2011;18:229-39
   PubMed Web of Science ®Google Scholar
• Kim SM, Oh JH, Park SA, Irradiation enhances the tumor tropism and therapeutic potential of TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. Stem Cells 2010;28:2217-28
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8
   PubMed Web of Science ®Google Scholar